UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~February~~March 256, 2017

PixarBio Corporation

(Name of Small Business Issuer in its Charter)

Delaware		47-1945113
(State or Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

200 Boston Avenue, Suite 1875

Medford, MA 02155

(Address of principal executive offices)

(617) 803-8838

(Telephone Number of Principal Executive Offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 Other Events.

OnPixarBio ~~February~~Corporation 25(the “Company”) has terminated, effective March 6, 2017, ~~PixarBio~~the ~~Corp~~consulting agreement of Dr. Robert S. Langer (~~the~~“Dr. ~~"Company"~~Langer”) ~~posted~~dated aJanuary ~~PowerPoint~~18, ~~presentation~~2015, onas ~~its~~amended ~~website~~August ~~entitled~~17, ~~“14-Day~~2016. The ~~NeuroRelease~~Company ~~Post-Surgical~~has ~~Pain~~also ~~Treatment~~terminated, ~~Pre-Clinical~~effective ~~Progress”~~March 6, 2017, Dr. ~~The~~Langer’s ~~PowerPoint~~position ~~presentation~~as isa ~~attached~~member asof ~~Exhibit~~the ~~99.1~~Company’s toScientific ~~this~~Advisory ~~Current~~Board. Dr. ~~Report~~Langer onwas ~~Form~~one 8of four co-Kfounders of the Company.

ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Pre-clinical Data Presentation dated February 25, 2017– 14-Day NeuroRelease Post-Surgical Pain Treatment Pre-Clinical Progress

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PixarBio Corporation (the Company)
Dated: February 28, 2017	By:	/s/ Francis M. Reynolds
Dated: March 10, 2017	By:	/s/ Francis M. Reynolds
		Francis M. Reynolds
	Name:	Francis M. Reynolds
	Title:	Chief Executive Officer

Filing Compare · PixarBio Corp